Cyclerion Therapeutics, Inc. - Special Call Transcript
Okay, great. Let's get started. Good morning. Welcome to our CNS-Focused Investor Event. We're pleased to have you join us. Today's webinar is going to be centered on IW-6463, our oral once-daily CNS-penetrant sGC stimulator. We want to tell you why we're so excited about its drug attributes and its therapeutic potential. And we want you to take a dive into the initial indications that we've selected to explore its full potential. And we'd like to describe to you the adaptive and learning approach that we're taking to development of this molecule.
Next slide, please. We're going to be making forward-looking statements during the course of this discussion. You can read our full safe harbor statement by accessing this presentation along with recent press releases on our website.
I am Peter Hecht, I'm the CEO, and I'll be your host for today. I'm joined by several of my colleagues, including members of the management team and our CNS program team. Given the short time together, we're not going to have introductions and have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |